Gene Edit Breakthrough Slashes Cholesterol

Sledgehammer smashing a tile labeled cholesterol — Photo: TuckerBlade / Shutterstock

A single infusion just knocked down a key cholesterol-driving protein by as much as 88 percent, and the effect held steady for a year and a half.

Quick Take

Eli Lilly’s experimental gene editor VERVE-102 cut PCSK9 protein by up to 88% and bad cholesterol by up to 62% after one dose
Results come from a 35-person trial published in the New England Journal of Medicine
Some patients kept lower cholesterol for at least 18 months with no serious treatment-related side effects reported
The therapy edits a single gene in liver cells, aiming to replace daily pills with a one-time shot

What The Trial Actually Tested

Doctors enrolled 35 adults with a genetic form of high cholesterol called heterozygous familial hypercholesterolemia, or with early heart disease, into an open-label study testing rising doses of VERVE-102. The trial, registered as NCT06164730, gave each patient a single intravenous infusion and then tracked their blood work over time to see how their cholesterol responded.

The tool works by editing one gene, PCSK9, directly inside liver cells. That gene normally tells the body to break down LDL receptors, the doors that pull bad cholesterol out of the bloodstream. Turn PCSK9 off permanently, and those doors stay open for good, at least in theory.

Patients in the highest dose group saw PCSK9 protein drop by up to 88 percent and LDL cholesterol fall by up to 62 percent. Researchers presented the numbers as a late-breaking finding at a major European heart conference the same day the New England Journal of Medicine published the full data.

Why This Gene Has Become A Top Target

PCSK9 has been a prime target in cardiology for over a decade because blocking it works so well. Injectable PCSK9 drugs already on the market lower cholesterol dramatically, but patients must keep taking them, often every few months, for life. That ongoing burden is exactly what a one-time gene edit is designed to erase.

Verve Therapeutics, the company Lilly partnered with on this program, has chased this idea since an earlier version of the drug, VERVE-101, showed promise but also raised concerns. That earlier trial saw temporary liver enzyme spikes and, in one medically fragile participant, a fatal cardiac arrest five weeks after treatment, a case regulators and researchers had to weigh carefully before moving forward.

The Data So Far, And What Comes Next

Researchers reported no dose-limiting toxic effects and no serious side effects tied directly to treatment in this newer study, a meaningfully cleaner safety picture than the earlier program produced. Investigators say effects lasted at least 18 months in patients who had follow-up data available that long, though not everyone in the trial has reached that mark yet.

Still, this remains early-stage evidence. Thirty-five patients is a small group, the study had no placebo comparison, and the trial measured cholesterol numbers rather than actual heart attacks or strokes prevented. Full completion of the study isn’t expected until August 2027, so the picture will keep filling in over the next two years.

A single injection of a new gene-editing therapy permanently reduces high cholesterol.

And it could eliminate the need for daily pills.

In a pioneering phase 1b clinical trial, researchers successfully tested VERVE-102, an investigational gene-editing therapy designed to target… pic.twitter.com/cWThsMgeWa

— Sir Khoi Khoi (@sir_khoi) August 23, 2026

Lilly has already framed this as a bet worth billions, betting that a permanent fix beats a lifetime of prescriptions and refills. That is a reasonable business instinct, and if larger trials confirm real drops in heart attacks and strokes, patients tired of daily pills and insurance hassles will have good reason to celebrate. For now, the data is genuinely encouraging, and it deserves to be watched closely rather than oversold.